Home Featured Page 181

Featured

Latest

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And...

PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for...

FILAMENT HEALTH ISSUED THIRD PATENT BY UNITED STATES PATENT AND TRADEMARK...

PT336 – Sisi Li, Ph.D. – Porta Sophia: Psychedelic Prior Art

Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic...

Psychedelic Research Bulletin: June 2022

Psychedelic Bulletin #110 – Psychedelics Docuseries Comes to Netflix; DEA Schedules...

FILAMENT HEALTH ANNOUNCES FIRST DOSING IN GROUNDBREAKING FDA-APPROVED PSILOCIN CLINICAL TRIAL

PT335 – Christopher Dawson & Andrew Galloway – Modernizing Traditional Plant...

Tripping the Reward Circuit: Psychedelics for Substance Use Disorders

EDITOR PICKS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Who Gets to Heal?

Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And...

PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for...

FILAMENT HEALTH ISSUED THIRD PATENT BY UNITED STATES PATENT AND TRADEMARK...

PT336 – Sisi Li, Ph.D. – Porta Sophia: Psychedelic Prior Art

Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic...

Psychedelic Research Bulletin: June 2022

Psychedelic Bulletin #110 – Psychedelics Docuseries Comes to Netflix; DEA Schedules...

FILAMENT HEALTH ANNOUNCES FIRST DOSING IN GROUNDBREAKING FDA-APPROVED PSILOCIN CLINICAL TRIAL

PT335 – Christopher Dawson & Andrew Galloway – Modernizing Traditional Plant...

Tripping the Reward Circuit: Psychedelics for Substance Use Disorders

EDITOR PICKS

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY